BACKGROUND: Podocalyxin is an anti-adhesive glycoprotein that has been associated with highly aggressive forms of cancers. Podocalyxin increases the migration and invasive properties of cancer cells through its interaction with ezrin, which undergoes an increase in phosphorylation through podocalyxin. AIMS: To study the roles of podocalyxin and phosphorylated ezrin (pEzrin) in uterine endometrioid adenocarcinoma (UEA). METHODS: Using immunohistochemisty the authors investigated the expression of podocalyxin and pEzrin along with some well-known markers of tumour aggressiveness including p53, oestrogen receptor and Ki-67 in UEA. RESULTS: Podocalyxin and pEzrin expression levels were positive in 36.1% (22 of 61 patients) and 50.8% (31 of 61 patients) of UEA cases, respectively. Further, podocalyxin expression was correlated with tumour grade (p=0.0001), FIGO stage (p=0.0062), p53 expression (p=0.0050) and Ki-67 index (p=0.0069). In addition, pEzrin expression was associated with FIGO stage (p=0.0231), p53 expression (p<0.0001) and Ki-67 index (p=0.0010). The expression of podocalyxin was also correlated with that of pEzrin (p=0.0102). CONCLUSIONS: These results suggest that overexpression of podocalyxin and pEzrin may indicate a more aggressive phenotype; thus, evaluation of these proteins may be useful in prediction of disease progression in UEA cases.
BACKGROUND:Podocalyxin is an anti-adhesive glycoprotein that has been associated with highly aggressive forms of cancers. Podocalyxin increases the migration and invasive properties of cancer cells through its interaction with ezrin, which undergoes an increase in phosphorylation through podocalyxin. AIMS: To study the roles of podocalyxin and phosphorylated ezrin (pEzrin) in uterine endometrioid adenocarcinoma (UEA). METHODS: Using immunohistochemisty the authors investigated the expression of podocalyxin and pEzrin along with some well-known markers of tumour aggressiveness including p53, oestrogen receptor and Ki-67 in UEA. RESULTS:Podocalyxin and pEzrin expression levels were positive in 36.1% (22 of 61 patients) and 50.8% (31 of 61 patients) of UEA cases, respectively. Further, podocalyxin expression was correlated with tumour grade (p=0.0001), FIGO stage (p=0.0062), p53 expression (p=0.0050) and Ki-67 index (p=0.0069). In addition, pEzrin expression was associated with FIGO stage (p=0.0231), p53 expression (p<0.0001) and Ki-67 index (p=0.0010). The expression of podocalyxin was also correlated with that of pEzrin (p=0.0102). CONCLUSIONS: These results suggest that overexpression of podocalyxin and pEzrin may indicate a more aggressive phenotype; thus, evaluation of these proteins may be useful in prediction of disease progression in UEA cases.
Authors: Kimberly A Snyder; Michael R Hughes; Bradley Hedberg; Jill Brandon; Diana Canals Hernaez; Peter Bergqvist; Frederic Cruz; Kelvin Po; Marcia L Graves; Michelle E Turvey; Julie S Nielsen; John A Wilkins; Shaun R McColl; John S Babcook; Calvin D Roskelley; Kelly M McNagny Journal: Breast Cancer Res Date: 2015-03-27 Impact factor: 6.466
Authors: Zev A Binder; I-Mei Siu; Charles G Eberhart; Colette Ap Rhys; Ren-Yuan Bai; Verena Staedtke; Hao Zhang; Nicolas R Smoll; Steven Piantadosi; Sara G Piccirillo; Francesco Dimeco; Jon D Weingart; Angelo Vescovi; Alessandro Olivi; Gregory J Riggins; Gary L Gallia Journal: PLoS One Date: 2013-10-16 Impact factor: 3.240
Authors: Maurice Canham; Chara Charsou; June Stewart; Sharon Moncur; Laura Hoodless; Ramya Bhatia; Duanduan Cong; Heather Cubie; Camille Busby-Earle; Alistair Williams; Victoria McLoughlin; John D M Campbell; Kate Cuschieri; Sarah Howie Journal: PLoS One Date: 2014-12-22 Impact factor: 3.240